Could a common blood thinner protect the brain after a burst aneurysm?

NCT ID NCT07493577

Not yet recruiting Disease control Sponsor: Dr David Hasan, M.D. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called tirofiban (Aggrastat) in 82 people who have had bleeding from a brain aneurysm. The drug is given through a vein to prevent blood clots that can cause delayed brain damage. The main goal is to find the safest dose, while also checking if it reduces complications like vasospasm and improves recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tirofiban (Aggrastat), a blood-thinning drug given intravenously
What this could lead to: If it works, this could point toward a treatment to reduce delayed brain injury after aneurysm bleeding.
What could go wrong: This is an early, small trial (82 people) focused on safety and dosing. The drug may not improve outcomes and carries bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEURYSMAL SUBARACHNOID HEMORRHAGE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aneurysmal subarachnoid hemorrhage subarachnoid hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEURYSMAL SUBARACHNOID HEMORRHAGE

Contacts and locations

Locations

Duke University Health System

Durham, North Carolina, 27710, United States
University of Texas Health Sciences Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.